Foucault, Derrida, Women's Speaking Justified, and Modelling Legal Argument

R. Loui

IF: 4.1

Artificial Intelligence and Law

Abstract:

What problem does this paper attempt to address?

Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation

Todd A Pezzi,Penny Fang,Olsi Gjyshi,Lei Feng,Suyu Liu,Ritsuko Komaki,Steven H Lin

DOI: https://doi.org/10.1001/jamanetworkopen.2020.1929

2020-04-01

Abstract:Importance: Historical data suggest that there is an overall survival benefit associated with prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC). However, as the fidelity of magnetic resonance imaging (MRI) of the brain continues to improve, this idea is now being questioned, with recent research showing no survival benefit associated with PCI in extensive-stage SCLC; however, the role for PCI is not clear in patients with limited-stage SCLC (LS-SCLC). Objective: To report the overall survival and rates of intracranial control for patients with LS-SCLC, all staged with MRI, who either did or did not undergo PCI. Design, setting, and participants: This cohort study included 297 patients with LS-SCLC at a large US academic cancer center. Patients were treated with thoracic radiation; 205 also underwent PCI and 92 did not. All patients underwent at least baseline MRI, with restaging brain MRI and/or computed tomography; they did not have disease progression after thoracic radiation treatment. A propensity score-matching analysis was undertaken in an attempt to adjust for potential bias. Of the 297 patients who met the inclusion criteria, the propensity score was calculated for 295 patients, using patient, tumor, and treatment characteristics. Data were analyzed in October 2019. Intervention: Prophylactic cranial irradiation in patients with LS-SCLC. Main outcomes and measures: The rate of overall survival and intracranial control. Results: Of the 297 patients, 162 (54.5%) were men. The median age was 62.2 years (range, 27.0-85.0 years) for patients who underwent PCI and 68.6 years (range, 40.0-86.0 years) for those who did not undergo PCI. The 3-year cumulative incidence rate of brain metastases was higher in the no-PCI group vs the PCI group, when counting death as a competing risk, but the difference was not statistically significant (20.40% [95% CI, 12.45%-29.67%] vs 11.20% [95% CI, 5.40%-19.20%]; P = .10). The use of PCI was not associated with a difference in overall survival between the patient groups (hazard ratio, 0.844; 95% CI, 0.604-1.180; P = .32). Conclusions and relevance: These findings suggest that patients with LS-SCLC staged with MRI who undergo PCI after thoracic radiation treatment were not associated with a decreased risk of developing new brain metastases compared with patients who do not undergo PCI. The use of PCI was not associated with an overall survival benefit for such patients.
Effects of brain radiotherapy strategies on survival in the era of MRI for patients with limited stage small cell lung cancer

Nan Yao,Zhaohui Qin,Meng Chen,Lingling Hu,Ji Ma,Jiaying Lu,Shaodong Tong,Na Li,Yuanhu Yao

DOI: https://doi.org/10.1186/s12885-024-12739-z

IF: 4.638

2024-08-05

BMC Cancer

Abstract:Background and purpose: In the context of the widespread availability of magnetic resonance imaging (MRI) and aggressive salvage irradiation techniques, there has been controversy surrounding the use of prophylactic cranial irradiation (PCI) for small-cell lung cancer (SCLC) patients. This study aimed to explore whether regular brain MRI plus salvage brain irradiation (SBI) is not inferior to PCI in patients with limited-stage SCLC (LS-SCLC). Methods: This real-world multicenter study, which was conducted between January 2014 and September 2020 at three general hospitals, involved patients with LS-SCLC who had a good response to initial chemoradiotherapy and no brain metastasis confirmed by MRI. Overall survival (OS) was compared between patients who did not receive PCI for various reasons but chose regular MRI surveillance and followed salvage brain irradiation (SBI) when brain metastasis was detected and patients who received PCI. Results: 120 patients met the inclusion criteria. 55 patients received regular brain MRI plus SBI (SBI group) and 65 patients received PCI (PCI group). There was no statistically significant difference in median OS between the two groups (27.14 versus 33.00 months; P = 0.18). In the SBI group, 32 patients underwent whole brain radiotherapy and 23 patients underwent whole brain radiotherapy + simultaneous integrated boost. On multivariate analysis, only extracranial metastasis was independently associated with poor OS in the SBI group. Conclusion: The results of this real-world study showed that MRI surveillance plus SBI is not inferior to PCI in OS for LS-SCLC patients who had a good response to initial chemoradiotherapy.
A Population-Based Analysis of Brain Metastasis Burden and Management in 8705 Small Cell Lung Cancer Patients

Karolina Gaebe,Anders Erickson,Natasha Leighl,Kelvin Chan,Benjamin Lok,Sunit Das

DOI: https://doi.org/10.1227/neu.0000000000002810_116

IF: 5.315

2024-04-01

Neurosurgery

Abstract:INTRODUCTION: Patients with small cell lung cancer (SCLC) have historically been characterised by poor overall survival (OS) and high risk for intracranial metastatic disease (IMD), but large-scale real-world evidence on clinical presentation and treatment in this population is lacking. These patients traditionally receive whole brain radiation therapy (WBRT) for IMD, however, a recent systematic review has indicated that OS following stereotactic radiosurgery (SRS) may be non-inferior compared with WBRT. METHODS: We included all patients diagnosed with SCLC between April 2007 and March 2018 identified through a provincial health administrative database. Information on patient and treatment characteristics, incidence and time to IMD, and OS from time of SCLC diagnosis were collected and analyzed using R. RESULTS: A total of 8705 patients were included. Median age was 68 years (range 18-103). Most patients presented with extensive disease (n = 5625) and were diagnosed after 2011 (n = 5768). Patients who received chemotherapy (n = 5563) had significantly longer OS than those who did not (median 10.64 vs 1.58 mo, HR 0.36, 95% CI 0.34-0.37). 6662 patients received brain imaging at the time of primary diagnosis (CT: 5126, MRI: 1536), and 88% of patients surviving longer than 6 mo received more than one follow-up brain scan. 31% developed IMD (synchronous: 1175, asynchronous: 1511) with median intracranial progression-free survival of 5.65 mo. Median OS of patients with IMD was 9.76 mo, 29 and 1300 received SRS and WBRT as first treatment for their IMD, respectively. OS was in favour of SRS over WBRT (median 20.47 vs 8.74 mo, HR 0.57, 95% CI 0.39-0.84), which remained significant in multivariate analysis (p < 0.001). CONCLUSIONS: OS for patients with SCLC remains poor and many patients present with IMD. Some patients with SCLC may benefit from SRS treatment.

surgery,clinical neurology
Role of nitric oxide in the inhibition of BMP-2-mediated stimulation of proteoglycan synthesis in articular cartilage.

P. M. van der Kraan,E. Vitters,H. V. van Beuningen,F. van de Loo,W. B. van den Berg

DOI: https://doi.org/10.1053/JOCA.1999.0275

IF: 7.507

2000-03-01

Osteoarthritis and Cartilage

Abstract:OBJECTIVE Bone morphogenetic protein-2 (BMP-2)-mediated stimulation of articular cartilage proteoglycan (PG) synthesis is suppressed in arthritic murine knee joints and by interleukin-1 (IL-1). The goal of this study was to investigate whether the gaseous mediator nitric oxide (NO) plays a crucial role in the inhibition of BMP-2 effects by IL-1. METHODS Bone morphogenetic protein-2 alone or in combination with IL-1 was injected into the right knee joint of wild-type and NOS2 deficient C57BI/6x129/Sv mice. Proteoglycan synthesis was measured ex vivo by incorporation of 35S-sulfate on day 1, 2 and 3 after injection. To study the role of NO in the inhibition BMP-2-mediated stimulation of PG synthesis in arthritic joints, BMP-2 was injected intra-articularly in the joints of wild-type and NOS2 deficient mice with zymosan-induced arthritis. To check for NOS2 deficiency, NO production was measured in conditioned medium after challenge of patellae with surrounding tissue with IL-1. RESULTS BMP-2 potently stimulated proteoglycan synthesis in articular cartilage of normal knees (up to 4-fold) but not in arthritic knees. Co-injection of BMP-2 with tumor necrosis factor alpha had no effect on BMP-2-mediated stimulation of PG synthesis but co-injection with IL-1 alpha resulted in a nearly total inhibition of BMP-2-mediated stimulation. In contrast, in NOS2 deficient mice IL-1 had no effect on BMP-2-mediated stimulation of PG synthesis. However, injection of BMP-2 into arthritic knee joints of NOS2 knock out mice did not result in significant stimulation of PG synthesis. CONCLUSIONS In this study we show that NO plays a role in the inhibition of BMP-2-mediated stimulation of PG synthesis by IL-1. However, NO, or at least NOS2, plays no dominant role in the inhibition of BMP-2 effects in arthritic knee joints.
Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis

Ryoko Suzuki,Xiong Wei,Pamela K Allen,James W Welsh,James D Cox,Ritsuko Komaki,Steven H Lin

DOI: https://doi.org/10.1186/s13014-018-1205-9

2018-12-29

Abstract:Background: Small cell lung cancer (SCLC) can recur in the brain after whole-brain irradiation (WBI). We documented outcomes after treatment of such recurrences and sought predictors of local control and overall survival (OS). Materials and methods: Eighty-five patients with SCLC and brain recurrence after prophylactic or therapeutic WBI in 1998-2015 were identified and data were extracted from the medical records. Survival was estimated with the Kaplan-Meier method, and univariate and multivariate Cox proportional hazards modeling was used to identify factors associated with OS or further brain progression. Results: Brain recurrence was treated by stereotactic radiosurgery (SRS) in 33 patients (39%), repeat WBI in 14 (16%), chemotherapy-only in 16 (19%), and observation in 22 (26%). Median OS time after brain recurrence (OSrec) was 4.3 months for all patients; 6-month OSrec rates were 58% after SRS, 21% after repeat WBI, 50% after chemotherapy-only, and 5% after observation (P < 0.001). Inferior OSrec was associated with poor performance status (ECOG score ≥ 3) and uncontrolled extracranial disease. Superior OSrec was associated with receipt of ≥4 chemotherapy cycles before brain recurrence and receipt of chemotherapy, SRS, or repeat WBI afterward. Receipt of chemotherapy after brain recurrence correlated with brain progression. Conclusions: Some patients with brain recurrence after WBI for SCLC can survive for extended periods with appropriate intervention, especially those with adequate performance status or controlled extracranial disease.
The role of prophylactic cranial irradiation in surgically resected combined small cell lung cancer: a retrospective study.

Yiting Wang,Jianlin Xu,Baohui Han,Qingquan Luo,Heng Zhao,Changxing Lv,Jiaming Wang,Jun Liu,Xiaolong Fu

DOI: https://doi.org/10.21037/jtd.2018.06.05

2018-01-01

Journal of Thoracic Disease

Abstract:Background: Combined small cell lung cancer (C-SCLC) is defined as small cell lung cancer (SCLC) combined with any of non-small cell lung cancer (NSCLC) histological types, such as large cell carcinoma, squamous cell carcinoma, or adenocarcinoma. Since C-SCLC is an increasingly recognized subtype of small cell carcinoma, we conducted a retrospective study in our institution to explore the value of prophylactic cranial irradiation (PCI) in patients with C-SCLC treated by surgery. Methods: Between 2005 and 2014, the records of all consecutive patients with pathologically diagnosed C-SCLC after surgery in our institution were reviewed. Overall survival (OS), disease-free survival (DFS), and brain metastasis free survival (BMFS) were estimated by Kaplan-Meier method. Survival differences were evaluated by log-rank test, while multivariate analysis was performed by a Cox proportional hazards model. Results: Of the total 91 patients included in this analysis, 11 patients (12.1%) were in PCI group and 80 (87.9%) in non-PCI group. The 5-year cumulative incidence of brain metastasis in the whole group was 22.2% (26.3% in non-PCI group vs. 0% in PCI group), and 5-year OS rate was 44.1%. Patients treated with PCI had significantly longer OS (P=0.011) and DFS (P=0.013), also had the trend to live a longer BM.FS with marginal significance (P=0.092) than non-PCI-treated patients. The multivariate analysis showed that PCI [hazard ratio (LIR) =0.102, P=0.024] was one of independent prognostic factors of the OS in surgery-treated C-SCLC patients. Conclusions: C-SCLC patients have a relative high risk of developing brain metastases based on our study. These data showed that PCI could improve OS and DFS, as well as tend to decrease brain metastases in surgically resected C-SCLC. However, whether PCI could be part of comprehensive treatment modalities in C-SCLC should be assessed in prospective studies.
Does protein kinase C regulate receptor agonists-mediated elevation in the cytosolic Ca2+ in human neutrophils?

H. Tuominen,L. Leino,K. Åkerman

DOI: https://doi.org/10.1006/BBRC.1994.2281

1994-09-15

Abstract:The feedback regulation of elevated cytosolic free Ca2+ concentrations ([Ca2+]i) by protein kinase C (PKC) in neutrophils was studied by two approaches. First, the PKC-activity was induced by phorbol 12-myristate 13-acetate (PMA) before the stimulation of Ca2+-signal with N-formyl-methionyl-leucyl-phenylalanine and serum-opsonized zymosan particles. Pretreatment of cells with PMA inhibited agonists-dependent Ca(2+)-transients. This inhibition was reversed by staurosporine. Second, the PKC-activity was induced simultaneously with the Ca(2+)-signal by the receptor agonists. In these conditions staurosporine had no effect on the Ca(2+)-response. In addition, the enhancement of PKC-activity, obtained by accumulating the endogenous PKC-activator diacylglycerol (DAG) with a DAG-kinase inhibitor, failed to change the agonists-stimulated elevations of [Ca2+]i. It is concluded that activation of PKC by PMA inhibits neutrophil Ca(2+)-responses, whereas receptor-mediated activation of PKC does not yield a negative feedback in elevated [Ca2+]i.
Stereotactic Radiosurgery in a Small Cell Lung Cancer Patient With Numerous Brain Metastases

Andrew Lian,Colton Ladbury,Arya Amini

DOI: https://doi.org/10.7759/cureus.28431

2022-08-26

Cureus

Abstract:Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by its propensity to metastasize to the brain. When SCLC patients develop brain metastasis, the standard-of-care treatment is whole-brain radiotherapy (WBRT), with the goal of treating both macroscopic and microscopic tumors. However, WBRT is found to be associated with significant morbidity including cognitive impairment. An emerging alternative to WBRT for SCLC is stereotactic radiosurgery (SRS), supported by a recent multi-institutional series and meta-analysis. However, there is limited evidence on the use of SRS when there are greater than 15 lesions from any histology, much less SCLC, where the risk of microscopic disease is felt to be even higher. Here, we present the case of an adult female with extensive-stage SCLC who developed 23 brain metastases. Due to patient preference, these were treated with SRS to a total dose of 20 Gy in one fraction. The patient did not experience any radiation-induced toxicity, including radionecrosis, and had overall favorable intracranial control using SRS alone at the time of her death, which was due to extracranial disease progression. This case adds to the literature suggesting that SRS could be a reasonable option for patients with SCLC. It illustrates that it might be reasonable to seek to expand on who might be considered a candidate for SRS treatment, with a high number of lesions not necessarily representing imminent widespread intracranial disease progression.
Effect of taurine on Ca,Mg-ATPase activity and platelet aggregation in man

V. A. Almazov,V. Gurevich,I. Mikhailova,E. N. Strel'stova

DOI: https://doi.org/10.1007/BF00837843

IF: 0.737

1985-10-01

Bulletin of Experimental Biology and Medicine

Abstract:
Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy

Joseph A Miccio,Andrew Barsky,Sarah Gao,Vivek Verma,Sonal S Noticewala,Vikram Jairam,Skyler B Johnson,James B Yu,James E Hansen,Sanjay Aneja,Yi An,Roy H Decker,S Bulent Omay,Jing Li,Goldie A Kurtz,Michelle Alonso-Basanta,John Y K Lee,Veronica L Chiang,Henry S Park

Abstract:Introduction: Patients with small cell lung cancer (SCLC) brain metastasis (BM) typically receive whole brain radiotherapy (WBRT) as data regarding upfront radiosurgery (SRS) in this setting are sparse. Methods: Patients receiving SRS for SCLC BM without prior brain radiation were identified at three U.S. institutions. Overall survival (OS), freedom from intracranial progression (FFIP), freedom from WBRT (FFWBRT), and freedom from neurologic death (FFND) were determined from time of SRS. Results: Thirty-three patients were included with a median of 2 BM (IQR 1-6). Median OS and FFIP were 6.7 and 5.8 months, respectively. Median FFIP for patients with ≤2 versus >2 BM was 7.1 versus 3.6 months, p=0.0303. Eight patients received salvage WBRT and the 6-month FFWBRT and FFND were 87.8%. and 90.1%, respectively. Conclusions: Most SCLC patients with BM who received upfront SRS avoided WBRT and neurologic death, suggesting that SRS may be an option in select patients.
MA12.06 A Study of the Prognosis of Patients with Limited-Stage SCLC Who Did Not Receive Prophylactic Cranial Irradiation after Chemoradiotherapy

X. Hu,F. Peng,M. Chen,Y. Kong,Y. Bao,Q. Zhang,Y. Xu

DOI: https://doi.org/10.1016/j.jtho.2021.01.258

IF: 20.121

2021-01-01

Journal of Thoracic Oncology

Abstract:To evaluate the prognosis of small cell lung cancer (SCLC) patients who did not receive prophylactic cranial irradiation (PCI) after effective initial standard thoracic radiotherapy and chemotherapy. Patients with limited-stage SCLC accrued in a prospective study were retrospectively analyzed. Those who had achieved complete remission (CR) or partial remission (PR) after radio-chemotherapy but did not receive PCI were selected. Kaplan Meier method was used to calculate survival data. The prognosis was analyzed using Cox proportional hazard regression model. Among 309 patients enrolled between June 2002 and January 2017, 275 patients achieved CR or PR after thoracic radiotherapy and chemotherapy, 82 patients did not receive PCI, 46 of them developed brain metastasis were analyzed in this study. The median time between brain metastasis and initial treatment was 5.5 months (2.9-26.6) and the median time between brain metastasis and the end of radiotherapy and chemotherapy was 1.7 months (0.2-24.0). Thirteen patients (28.3%) detected brain metastases before PCI, 24 patients (52.2%) had multiple brain metastases (≥ 3), 18 patients (39.1%) had symptomatic brain metastases, and 21 patients (45.7%) had control / slow progress of extracranial diseases. Thirty-three patients had complete treatment data for brain metastasis. Among them, 19 patients (57.6%) received brain radiotherapy alone, 4 patients (12.1%) received chemotherapy alone, 6 patients (18.2%) received brain radiotherapy and chemotherapy, and 4 patients (12.1%) did not receive treatment. The median survival time after brain metastasis was 7.0 months (95% CI: 4.6-9.3), and the overall survival rates of 1 year and 3 years were 32.6% and 3.3%, respectively. The median survival time of patients who received radiotherapy alone, chemotherapy alone and combined therapy were 8.3 months (4.7-11.8), 3.2 months (0.0-8.5), and 30.5 months (0.0-78.1) respectively (P = 0.000). Multivariate analysis showed that multiple brain metastases was a negative prognostic factors (HR: 3.59, 95% CI: 1.37-9.36, P = 0.009), brain radiotherapy (HR: 0.09, 95% CI: 0.02-0.37, P = 0.001), systemic chemotherapy (HR: 0.11, 95% CI: 0.02-0.61, P = 0.01) were favorably associated with overall survival. Patients with SCLC who did not receive PCI tended to develop brain metastasis and had poor prognosis. PCI is highly recommended in patients who achieved CR and PR after thoracic radiotherapy and chemotherapy. Brain radiotherapy combined with chemotherapy could improve survival for patients with brain metastasis.
Prophylactic cranial irradiation in patients with resected small‐cell lung cancer: A systematic review and meta‐analysis

Haoning Peng,Jianqi Hao,Bo Dong,Minqi Chen,Zongyuan Li,Cong Chen,Lunxu Liu

DOI: https://doi.org/10.1111/1759-7714.15463

IF: 3.223

2024-10-10

Thoracic Cancer

Abstract:We conducted a meta‐analysis to evaluate the efficacy of prophylactic cranial irradiation (PCI) in resected small‐cell lung cancer (SCLC) patients. The use of PCI delayed brain recurrence and improved overall survival in patients with resected, stage I–III SCLC. Importantly, patients with N0 SCLC can also benefit from postoperative PCI. Prophylactic cranial irradiation (PCI) was recommended for limited‐stage small‐cell lung cancer (SCLC) patients with complete or partial response to primary chemoradiotherapy. But it is still controversial regarding its role in SCLC patients who have had radical resection. This meta‐analysis aims to evaluate the efficacy of PCI in resected SCLC patients. We searched PubMed, EMBASE, Web of Science, CENTRAl, and ClinicalTrials for controlled trials and cohort studies regarding PCI in postoperative SCLC patients. The correlation between PCI and post‐operative outcomes in SCLC patients, including survival and brain metastasis rate (BMR), was examined using hazard ratios (HRs) and risk ratios with corresponding 95% confidence intervals. Quality of studies was assessed by the Newcastle–Ottawa Scale (NOS), and publication bias was assessed by Begg's test. Meta‐analysis of eight studies with 2688 patients in total showed PCI was associated with improved overall survival (OS) for resected SCLC (HR: 0.65, 95% CI: 0.57–0.75, p

oncology,respiratory system
Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer.

Jianlin Xu,Haitang Yang,Xiaolong Fu,Bo Jin,Yuqing Lou,Yanwei Zhang,Xueyan Zhang,Hua Zhong,Huimin Wang,Dan Wu,Baohui Han

DOI: https://doi.org/10.1016/j.jtho.2016.09.133

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:Data on prophylactic cranial irradiation (PCI) after complete resection of SCLC are limited. The purpose of this study was to investigate the impact of PCI in this population.We retrospectively identified completely resected SCLC at the Shanghai Chest Hospital between January 2006 and January 2014.A total of 349 patients (115 patients who received PCI [the PCI-treated cohort] and 234 patients who did not [the non-PCI-treated cohort]) were included in the study. The results demonstrated that the PCI-treated cohort had longer overall survival than the non-PCI-treated cohort among patients with pathologic stage (p-stage) II (hazard ratio [HR] = 0.54, 95% confidence interval [CI]: 0.30-0.99, p = 0.047) and p-stage III (HR = 0.54, 95% CI: 0.34-0.86, p = 0.009) disease. Among patients with p-stage III disease, there was a significantly higher risk for cerebral recurrence from the time of diagnosis in the non-PCI-treated cohort (p = 0.018). With regard to patients with p-stage I disease, neither overall survival benefit (HR = 1.61, 95% CI: 0.68-3.83, p = 0.282) nor risk for cerebral recurrence (p = 0.389) was significant between the PCI-treated and non-PCI-treated cohorts.The data presented in the current study support using PCI in patients with p-stage II/III disease but not in patients with p-stage I disease. A relatively lower risk for brain metastases in p-stage I patients might explain the inferior efficacy of PCI in this population.
Determination of platinum metals and gold by optical emission spectrometry with a radiofrequency inductively-coupled argon plasma source.

G. Kirkbright,H. M. Tinsley

DOI: https://doi.org/10.1016/0039-9140(79)80151-4

Abstract:
Stereotactic radiosurgery for brain metastases from small cell lung cancer without prior whole-brain radiotherapy: A meta-analysis

G A Viani,A G Gouveia,A V Louie,F Y Moraes

DOI: https://doi.org/10.1016/j.radonc.2021.06.026

Abstract:Objectives: Assess upfront Stereotactic radiosurgery (SRS) effectiveness for small cell lung cancer (SCLC) brain metastases (BM). Where possible, a comparison with whole-brain radiotherapy (WBRT) was performed. Methods: Following PRISMA and MOOSE guidelines, eligible studies were identified on Medline, Embase, Cochrane Library, and proceedings of annual meetings between inception and July 01, 2020. Results: Nine observational studies with 1638 patients were included. The median overall survival (OS) was 8.3 months (95% CI 7.1-9.5 months, I2 = 0%). OS rate at 12 months was 39% (95% CI 31-44%, I2 = 0%). The relative risk between SRS and WBRT for the OS at 12 months was 1.33 (95% CI 1.13-1.51, P = 0.0001). The projected OS for 6, 12, 18- and 24-months comparing SRS with WBRT was 67% vs. 57%, 39% vs. 29%, 22% vs. 15% and 15% vs 9%, favoring SRS (P < 0.001). The LC rate at 12 months was 93% (95% CI 91-94%, I2 = 0%). The distant brain failure rate (DBFR) at 12 months was 41% (95% CI 33-48%, I2 = 52%, P = 0.08). The SRS or WBRT as salvage treatment after upfront SRS was 32% and 19%, respectively. The freedom from neurologic death at 12 months was 87% (95% CI 84-89%). Conclusion: Based on the pooling of a large sample of retrospective studies our meta-analysis suggests that for high selected SCLC patients with limited BM upfront SRS produces favorable lesion control and survival outcomes. These findings support the design of randomized clinical trial to confirm the role of SRS in this clinical scenario.
Stereotactic radiosurgery for recurrent pediatric brain tumors: clinical outcomes and toxicity

Elyn Wang,Paulina M Gutkin,Justin Oh,Erqi Pollom,Scott G Soltys,Gerald A Grant,Laura M Prolo,Steven Chang,Gordon Li,Paul G Fisher,Sonia Partap,Cynthia J Campen,Iris C Gibbs,Susan M Hiniker

DOI: https://doi.org/10.3171/2022.8.FOCUS22361

Abstract:Objective: Recurrence of brain tumors in children after the initial course of treatment remains a problem. This study evaluated the efficacy and safety of reirradiation using stereotactic radiosurgery (SRS) in patients with recurrent pediatric primary brain tumors. Methods: This IRB-approved retrospective review included pediatric patients with recurrent primary brain tumors treated at Stanford University from 2000 to 2019 using frameless SRS. Time to local failure (LF) and distant intracranial failure (DIF) were measured from the date of SRS and analyzed using competing risk analysis. Overall survival (OS) and progression-free survival (PFS) were analyzed with the Kaplan-Meier method. Results: In total, 37 patients aged 2-24 years (median age 11 years at recurrence) were treated for 48 intracranial tumors. Ependymoma (38%) and medulloblastoma (22%) were the most common tumor types. The median (range) single fraction equivalent dose of SRS was 16.4 (12-24) Gy. The median (range) follow-up time was 22.9 (1.5-190) months. The median OS of all patients was 36.8 months. Eight of 40 (20%) lesions with follow-up imaging locally recurred. The 2-year cumulative incidence of LF after reirradiation with SRS was 12.8% (95% CI 4.6%-25.4%). The 2-year cumulative incidence of DIF was 25.3% (95% CI 12.9%-39.8%). The median PFS was 18 months (95% CI 8.9-44). Five (10.4%) patients developed toxicities potentially attributed to SRS, including cognitive effects and necrosis. Conclusions: Reirradiation using SRS for recurrent pediatric brain tumors appears safe with good local control. Innovations that improve overall disease control should continue because survival outcomes after relapse remain poor.
Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis

Xin Yin,Danfang Yan,Miao Qiu,Liming Huang,Sen-Xiang Yan

DOI: https://doi.org/10.1186/s12885-018-5251-3

IF: 4.638

2019-01-21

BMC Cancer

Abstract:BackgroundThe efficacy of prophylactic cranial irradiation (PCI) in treating patients with small cell lung cancer (SCLC) has not been clear, and recent randomized studies have demonstrated conflicting results from previously published findings. The purpose of this study was to reevaluate the efficacy of PCI in patients with SCLC and to assess factors associated with its efficacy.MethodsWe conducted a quantitative meta-analysis to explore the efficacy of PCI in patients with SCLC. A literature search was performed using EMBASE, MEDLINE, Cochrane and ClinicalTrials.gov databases. We pooled the data and compared overall survival (OS) and brain metastasis (BM) between patients treated with PCI (PCI group) and patients without PCI treatment (observation group).ResultsOf the 1074 studies identified in our analysis, we selected seven studies including 2114 patients for the current meta-analysis. Our results showed that the PCI group showed decreased BM (HR = 0.45, 95% CI: 0.38–0.55, P < 0.001) and prolonged OS (HR = 0.81, 95% CI: 0.67–0.99, P < 0.001). However, in terms of OS, the pooled analysis showed a high heterogeneity (I2 = 74.1%, P = 0.001). In subgroup analyses of OS, we found that the heterogeneity mainly came from patients with brain imaging after initial chemoradiotherapy (HR = 0.94, 95% CI: 0.74–1.18, P = 0.59).ConclusionsThe results of this study showed that PCI has a significant effect on decreasing BM but little benefit in prolonging OS when brain imaging was introduced to confirm lack of BM after initial chemoradiotherapy and before irradiation.

oncology
Prophylactic Cranial Irradiation for Limited‐stage Small‐cell Lung Cancer in the Magnetic Resonance Imaging Era

Lihua Pan,Xingwen Fan,Lifang Wang,Yihua Wang,Yaqi Li,Yingshan Cui,Hong Zheng,Qiong Yi,Kailiang Wu

DOI: https://doi.org/10.1002/cam4.5082

IF: 4.711

2022-01-01

Cancer Medicine

Abstract:Abstract Background We investigated the role of prophylactic cranial irradiation (PCI) in limited‐stage small‐cell lung cancer (LS‐SCLC) according to tumor response in the magnetic resonance imaging (MRI) era. Methods We retrospectively evaluated patients with LS‐SCLC without brain metastases (BMs) on MRI who achieved either complete response (CR) or partial response (PR) after initial chemoradiotherapy at our center from 2006 to 2017. Results This study comprised 116 patients (median age, 58 years; men, 92; women, 24). After initial chemoradiotherapy, 53 patients achieved CR, while 63 patients achieved PR. Eighty‐three patients received PCI. Patients who received PCI had better overall survival (OS, 5‐year: 52.5% vs. 35.1%; p = 0.012) and progression‐free survival (PFS, 5‐year: 45.0% vs. 28.2%; p = 0.001) and a lower incidence of BMs (5‐year: 18.3% vs. 39.4%; p = 0.010). In the subgroup analysis, PCI improved OS (5‐year: 67.8% vs. 46.7%, p = 0.005) and PFS (5‐year: 65.2% vs. 35.0%, p = 0.021) and decreased BM risk (5‐year: 12.1% vs. 52.4%, p = 0.002) for patients with CR. However, PCI had no benefit (5‐year OS: 40.5% vs. 35.6%, p = 0.763; 5‐year BMs: 24.6% vs. 31.9%, p = 0.561) for patients with PR. Conclusions Tumor response remained an important factor for selecting patients for PCI in the MRI era. PCI should be recommended for patients with LS‐SCLC who achieve CR after initial thoracic chemoradiotherapy.
Long-term survival in patients with brain-only metastatic non-small cell lung cancer undergoing upfront intracranial stereotactic radiosurgery and definitive treatment to the thoracic primary site

K. Salari,J.S. Lee,H. Ye,Z.A. Seymour,K.C. Lee,P. Chinnaiyan,I.S. Grills

DOI: https://doi.org/10.1016/j.radonc.2024.110262

IF: 6.901

2024-03-31

Radiotherapy and Oncology

Abstract:Background and purpose To evaluate modern clinical outcomes for patients with brain-only metastatic non-small cell lung cancer (NSCLC) treated with intracranial stereotactic radiosurgery (SRS) with or without definitive treatment of the primary site. Materials and methods Patients with synchronously diagnosed NSCLC and brain-only metastatic disease treated with intracranial SRS at a single institution were retrospectively identified. Patients were stratified based on whether they did (A) or did not (B) receive definitive primary site treatment. Patient characteristics and clinical outcomes were compared. Results From 2008 to 2022, 103 patients were identified, 53 of whom received definitive primary site treatment. Median follow-up was 2.1 y (A) and 0.8 y (B) (p < 0.001). 28 (53 %) patients in Group A received immune checkpoint inhibitor (ICI) therapy versus 19 (38 %) in Group B (p = 0.13) and there were no other statistically significant baseline or treatment characteristic differences between the groups. 5-year local-PFS was 34.5 % (A) versus 0 % (B) (p < 0.001). 5-year regional-PFS was 33.0 % (A) versus 0 % (B) (p < 0.001). 5-year distant body-PFS was 34.0 % (A) versus 0 % (B) (p < 0.001). 5-year CNS-PFS was 14.7 % (A) versus 0 % (B) (p = 0.12). 5-year OS was 40.2 % (A) versus 0 % (B) (p = 0.001). 5-year CSS was 67.6 % (A) versus 0 % (B) (p = 0.002). On multivariable analysis, lack of definitive treatment to the primary site (HR = 2.40), AJCC T3-4 disease (HR = 2.73), and lack of ICI therapy (HR = 2.86) were significant predictors of death. Conclusion Definitive treatment to the thoracic primary site in patients with brain-only metastatic NSCLC after intracranial radiosurgery was associated with slower progression of disease and improved survival.

oncology,radiology, nuclear medicine & medical imaging
A study of the prognosis of patients with limited-stage small cell lung cancer who did or did not receive prophylactic cranial irradiation after effective chemoradiotherapy

Qing Wu,Mengyuan Chen,Fang Peng,Qun Zhang,Yue Kong,Yong Bao,Yujin Xu,Xiao Hu,Ming Chen

DOI: https://doi.org/10.3389/fonc.2023.1118371

IF: 4.7

2023-03-23

Frontiers in Oncology

Abstract:Objective To investigate the prognosis of patients with LS-SCLC who responded to chest chemoradiotherapy but did not receive PCI. Methods A retrospective analysis was conducted on LS-SCLC patients who had achieved complete remission (CR) or partial remission (PR) after definitive chemoradiotherapy but did not receive PCI. The survival rates were calculated using Kaplan–Meier method. The prognosis was analyzed using Cox proportional hazard regression model. The main endpoint was OS. Results Of the 500 patients with LS-SCLC admitted between June 2002 and January 2018, 327 achieved CR or PR after definitive chest chemoradiotherapy, 103 did not receive PCI, and 63 of them developed brain metastases (BM). The 1-year and 3-year OS rates in PCI group were 87.5% and 42.3% respectively, versus 70.4% and 20.9% for non-PCI group(P=0.002). The median survival time after BM was 8.7 months (range: 0.3-48.7), and 3-year OS rate was 15.0%, the median survival time of patients without BM was 20.1 months (range: 2.9-79.4), and 3-year OS was 33.4% (P=0.014). Patients with BM were subsequently treated with palliative therapy. Multivariate analysis showed that compared with no treatment, brain radiotherapy alone (HR: 0.131, 95%CI: 0.035-0.491, P=0.003) and radiotherapy combined with chemotherapy (HR: 0.039, 95%CI: 0.008-0.194, P<0.001) significantly reduced the risk of death. Multiple BM (HR: 2.391, 95%CI: 1.082-5.285, P=0.031) was an independent adverse prognostic factor for OS. Conclusion LS-SCLC patients who achieved good response after chest chemoradiotherapy without receiving PCI were prone to develop BM and have a poor prognosis. Multiple BM was an independent adverse prognostic factor. PCI remains the standard of care for LS-SCLC patients.

oncology

Foucault, Derrida, Women's Speaking Justified, and Modelling Legal Argument

Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation

Effects of brain radiotherapy strategies on survival in the era of MRI for patients with limited stage small cell lung cancer

A Population-Based Analysis of Brain Metastasis Burden and Management in 8705 Small Cell Lung Cancer Patients

Role of nitric oxide in the inhibition of BMP-2-mediated stimulation of proteoglycan synthesis in articular cartilage.

Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis

The role of prophylactic cranial irradiation in surgically resected combined small cell lung cancer: a retrospective study.

Does protein kinase C regulate receptor agonists-mediated elevation in the cytosolic Ca2+ in human neutrophils?

Stereotactic Radiosurgery in a Small Cell Lung Cancer Patient With Numerous Brain Metastases

Effect of taurine on Ca,Mg-ATPase activity and platelet aggregation in man

Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy

MA12.06 A Study of the Prognosis of Patients with Limited-Stage SCLC Who Did Not Receive Prophylactic Cranial Irradiation after Chemoradiotherapy

Prophylactic cranial irradiation in patients with resected small‐cell lung cancer: A systematic review and meta‐analysis

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer.

Determination of platinum metals and gold by optical emission spectrometry with a radiofrequency inductively-coupled argon plasma source.

Stereotactic radiosurgery for brain metastases from small cell lung cancer without prior whole-brain radiotherapy: A meta-analysis

Stereotactic radiosurgery for recurrent pediatric brain tumors: clinical outcomes and toxicity

Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis

Prophylactic Cranial Irradiation for Limited‐stage Small‐cell Lung Cancer in the Magnetic Resonance Imaging Era

Long-term survival in patients with brain-only metastatic non-small cell lung cancer undergoing upfront intracranial stereotactic radiosurgery and definitive treatment to the thoracic primary site

A study of the prognosis of patients with limited-stage small cell lung cancer who did or did not receive prophylactic cranial irradiation after effective chemoradiotherapy